[
  {
    "ts": null,
    "headline": "Stock market sell-off: Why these stocks are in the green amid the pain",
    "summary": "The shift to defense is on.",
    "url": "https://finnhub.io/api/news?id=b4817b2db1f2b2841b7c6941f4f1d8c6378ba55c52a7c3036a715bd6ab90bb31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741630632,
      "headline": "Stock market sell-off: Why these stocks are in the green amid the pain",
      "id": 133184559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The shift to defense is on.",
      "url": "https://finnhub.io/api/news?id=b4817b2db1f2b2841b7c6941f4f1d8c6378ba55c52a7c3036a715bd6ab90bb31"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
    "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741625200,
      "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
      "id": 133127786,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220400589/image_1220400589.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96"
    }
  },
  {
    "ts": null,
    "headline": "Amgen : Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products",
    "summary": "Amgen Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...",
    "url": "https://finnhub.io/api/news?id=4f36151ad6c811da06182b548d3769fb6f8924626ca5419c49780b2c29b9421f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741621324,
      "headline": "Amgen : Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products",
      "id": 133125713,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...",
      "url": "https://finnhub.io/api/news?id=4f36151ad6c811da06182b548d3769fb6f8924626ca5419c49780b2c29b9421f"
    }
  },
  {
    "ts": null,
    "headline": "AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies",
    "summary": "Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.",
    "url": "https://finnhub.io/api/news?id=58ef0150b41d2233a520d9bd77af4d5b028c9786dd73f802323e68c42b56be10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741613220,
      "headline": "AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies",
      "id": 133185014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.",
      "url": "https://finnhub.io/api/news?id=58ef0150b41d2233a520d9bd77af4d5b028c9786dd73f802323e68c42b56be10"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
    "summary": "THOUSAND OAKS, TOKYO - Amgen and Kyowa Kirin Co., Ltd. today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell...",
    "url": "https://finnhub.io/api/news?id=9f19f7cbf57d1b3d4633eaa509b89e40e9ceba9443c1c02f5b391929fe87e35a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610357,
      "headline": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
      "id": 133122070,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "THOUSAND OAKS, TOKYO - Amgen and Kyowa Kirin Co., Ltd. today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell...",
      "url": "https://finnhub.io/api/news?id=9f19f7cbf57d1b3d4633eaa509b89e40e9ceba9443c1c02f5b391929fe87e35a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints",
    "summary": "All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.",
    "url": "https://finnhub.io/api/news?id=02e3b86c71c90876f8699724049e65d0639a7cf7d52e91575d0f4a6016284b82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741606232,
      "headline": "Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints",
      "id": 133185015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.",
      "url": "https://finnhub.io/api/news?id=02e3b86c71c90876f8699724049e65d0639a7cf7d52e91575d0f4a6016284b82"
    }
  },
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus",
    "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
    "url": "https://finnhub.io/api/news?id=cd3c8dc42f251d0f61122a72c4eecd5eaf425f1142d318169c9f4cfd57c4a4b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741602900,
      "headline": "Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus",
      "id": 133185016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
      "url": "https://finnhub.io/api/news?id=cd3c8dc42f251d0f61122a72c4eecd5eaf425f1142d318169c9f4cfd57c4a4b6"
    }
  }
]